Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2020-06-29 Declaration of Voting R…
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
Result of Annual General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement from Mereo BioPharma regarding the 'Result of Annual General Meeting'. It explicitly lists the voting results for various resolutions and confirms that all resolutions were passed. This aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2020-06-29 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings', which is the regulatory standard in the UK for disclosing changes in significant share ownership. It explicitly identifies the issuer (Mereo BioPharma Group plc) and the person subject to the notification (Acacia Research Corporation), detailing the crossing of a voting rights threshold. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2020-06-22 English
Second Price Monitoring Extn
Regulatory Filings Classification · 100% confidence The document is a short regulatory notification from the London Stock Exchange (RNS) regarding a 'Second Price Monitoring Extension' for Mereo BioPharma Group plc. It does not contain financial statements, management reports, or specific corporate actions like dividends or board changes. As it is a standard regulatory market announcement that does not fit into the other specific categories, it is classified as a Regulatory Filing (RNS).
2020-06-22 English
Price Monitoring Extension
Regulatory Filings Classification · 100% confidence The document is a short notification from the London Stock Exchange regarding a 'Price Monitoring Extension' for a specific security. It is distributed via the RNS (Regulatory News Service) and does not contain financial statements, management reports, or other substantive corporate disclosures. As it is a standard regulatory notification regarding trading parameters that does not fit into specific categories like M&A or dividends, it is classified as a general regulatory filing.
2020-06-22 English
6-K
Annual Report Classification · 95% confidence The document is a Form 6-K filing by Mereo BioPharma Group plc, reporting financial results for the year ended December 31, 2019. It includes detailed financial highlights, operational progress, clinical trial updates, and strategic developments. The document references the filing of the Form 20-F annual report with the SEC and provides a summary of the company's annual financial and operational performance. The length of the document (15,000 characters) and the presence of substantive financial data and management commentary indicate this is a comprehensive report rather than a brief announcement or certification. Form 6-K is used by foreign private issuers to report material information, often including interim or annual financial results. Given the detailed financial results for a full fiscal year and operational updates, this filing aligns best with an Annual Report (10-K equivalent for foreign issuers) rather than a simple announcement or regulatory filing. Therefore, the appropriate classification is Annual Report (10-K).
2020-06-16 English
Final Results for the year ended December 31, 2019
Regulatory Filings Classification · 98% confidence The document is an 'Earnings Release' (ER). It is titled 'Financial Results for the Year Ended December 31, 2019', contains key financial highlights (cash resources, loss after tax, net cash used), and includes management commentary on operational progress and outlook. While it mentions that the full annual report is available on the website, the document itself provides the summary of financial results, which is the hallmark of an Earnings Release. It is not a full 10-K, but rather the initial announcement of the annual financial results.
2020-06-16 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.